| 0.5677 -0.149 (-20.82%) | 12-31 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.96 |
1-year : | 1.16 |
| Resists | First : | 0.82 |
Second : | 1 |
| Pivot price | 0.75 |
|||
| Supports | First : | 0.54 |
Second : | 0.45 |
| MAs | MA(5) : | 0.72 |
MA(20) : | 0.77 |
| MA(100) : | 0.69  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 34.1 |
D(3) : | 50.8 |
| RSI | RSI(14): 37.1 |
|||
| 52-week | High : | 1.42 | Low : | 0.23 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BCAB ] has closed below the lower bollinger band by 23.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.83 | 0.83 - 0.83 |
| Low: | 0.54 - 0.55 | 0.55 - 0.55 |
| Close: | 0.56 - 0.57 | 0.57 - 0.57 |
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Wed, 31 Dec 2025
BioAtla Stock Slips Premarket After Early Pop As Investors Weigh $40M SPV Deal For Phase 3 Cancer Trial - Stocktwits
Wed, 31 Dec 2025
BioAtla Signs Multiple Material Agreements - TradingView — Track All Markets
Wed, 31 Dec 2025
$40M AI-driven cancer deal backs new OPSCC drug into Phase 3 test - Stock Titan
Fri, 21 Nov 2025
BioAtla, Inc. Secures $7.5 Million Financing to Support Operations During Strategic Partnership Negotiations - Quiver Quantitative
Thu, 20 Nov 2025
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 11 (%) |
| Held by Institutions | 28.6 (%) |
| Shares Short | 6,190 (K) |
| Shares Short P.Month | 4,520 (K) |
| EPS | -1.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.53 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -105.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.8 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.11 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -57 (M) |
| Levered Free Cash Flow | -33 (M) |
| PE Ratio | -0.5 |
| PEG Ratio | 0 |
| Price to Book value | -1.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|